Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.81 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.81 |
| ▸ | BRAF | P15056 | 10/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144146 | 0.93 | RAF1 (0.80) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25144197 | 0.92 | RAF1 (0.84) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL963243 | 0.92 | RAF1 (0.84) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25144199 | 0.92 | RAF1 (0.84) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL31190228 | 0.92 | RAF1 (0.84) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25144447 | 0.91 | RAF1 (0.82) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL31103740 | 0.91 | RAF1 (0.82) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25144179 | 0.91 | RAF1 (0.82) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25143927 | 0.91 | RAF1 (0.82) | RAF1MAP2K1BRAFCYP3A4CYP2C9 | |
| SCHEMBL25144180 | 0.91 | RAF1 (0.73) | RAF1MAP2K1BRAFCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235356-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023147297-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023108110-A2 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023081676-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023076991-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230119327-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | IMMUNEERING CORPORTAION | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119327-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | BRAF, NRAS, RAF1 | RAF1 3/4885MAP2K1 57/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.